Metagonimiasis

Summary

Metagonimiasis (MONDO:0004666) is a disease and 1 clinical trial. Top therapeutic interventions include entecavir anhydrous. A subtype of helminthiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	metagonimiasis
Mondo ID	MONDO:0004666
DOID	DOID:884
ICD-11	844727447
NCIT	C128390
SNOMED CT	37832003
UMLS	C0025530
MedGen	7564
Is cancer (heuristic)	no

Also known as: infection by Metagonimus yokogawai · infections, Metagonimus yokogawai · Metagonimus yokogawai infection

Disease family

This is a subtype of helminthiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › metagonimiasis

Related subtypes (21): acanthocephaliasis, heterophyiasis, fascioliasis, fasciolopsiasis, monieziasis, clonorchiasis, dicrocoeliasis, echinostomiasis, fascioloidiasis, gnathomiasis, hymenolepiasis, necatoriasis, Nematoda infectious disease, opisthorchiasis, paragonimiasis, trichostrongyloidiasis, schistosomiasis, filariasis, angiostrongyliasis, intestinal helminthiasis, Cestode infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05687409	PHASE4	COMPLETED	Synbiotics Interventions for Managing Cirrhosis and Its Complications

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ENTECAVIR ANHYDROUS	4	3